anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Surgical technique All robotic surgical procedures were performed by a single highly experienced robotic surgeon (AM) alternated with the other fellow-members. The Da Vinci Si system, (Intuitive Surgical, Sunnyvale, CA, USA), in a four-arm conﬁguration with a 0/30° laparoscope was used for all cases. As previously described (4), patients are positioned in 30° Trendelenburg with a standard six-port transperitoneal approach for the demolitive part and then reduced to 20° to facilitate bowel handling and urethro-neobladder anastomosis. After the isolation of 45-50 cm of ileum, the urethro-ileal anastomosis is performed obtaining an asymmetrical 'U'-shape (25-30 cm distally and 20 cm proximally to anastomosis). Ileum is then sectioned by endo- GIA 60 mm Echelon Powered Endopath Stapler (Ethicon Inc., Cincinnati, OH, USA) and the intestinal continuity is then restored with an intracorporeal side-to-side anastomosis with one longitudinal fire. The two transversal holes are closed by a double layer 3-0 Stratafix running suture. The asymmetrical 'U'-shape segment is then detubularized and the posterior plate is reconfigured as an "Γ", by suturing the span of the arms of the 'U' aligned in parallel, and by placing the extending portion of the loop distally to the right, forming the short arm of the "Γ". Neobladder neck configuration was performed by suturing a tract of 2-5 cm longitudinally from the 12 o'clock position of the anastomosis. Then, the posterior plate was folded anteriorly, distal to proximally, roughly 5 cm right from the proximal edge of the posterior closure with the goal of creating two symmetrical segments.

Ureteral reimplantation After a careful isolation of the ureters avoiding iatrogenic blood supply damages, the ureteric stumps were sectioned and adequately spatulated. Bilateral ureteral reimplantation was then performed orthotopically and directly with no anti-reflux mechanisms on the lateral side of each anterior segment with mucosa-mucosa inverted sutures. In case of stentless procedure the anastomosis was performed directly while mono J ureteral catheters were employed in case of stent placement. The anterior plate was therefore closed by an "∧" -shaped suture. Both mono J stents were passed through the closing of the two anterior plates in the stent group.
Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
Mitral regurgitation is one of the most prevalent valvulopathies with a disease burden that incurs significant healthcare costs globally. Surgical repair of the posterior mitral valve leaflet is a standard treatment, but approaches for repairing the anterior mitral valve leaflet are not widely established. Since anterior leaflet involvement is less common and more difficult to repair, fewer studies have investigated its natural history and treatment options. In this review, we discuss surgical techniques for repairing the anterior leaflet and their outcomes, including survival, reoperation, and recurrence of regurgitation. We show that most patients with mitral regurgitation from the anterior leaflet can be repaired with good outcomes if performed at centers with expertise. Additionally, equal consideration for early repair should be given to patients with mitral regurgitation from both anterior and posterior pathology. However, more studies to better evaluate the efficacy and safety of anterior mitral valve leaflet repair are needed.
The invention relates to a medicinal wine recipe for anesthesia or acesodyne, in particular to an analgetic medicinal wine. The invention provides the medicinal wine which solves the analgetic anesthesia by the traditional Chinese medicinal wine. The medicinal wine comprises the following compositions: Chinese azalea, angelica, jasmine flower, pinelliae tuber, calamus, ginseng, liquorice root, tangerine peel, swallowwort root, poria cocos, aconitum tip, arisaema tuber, pepper, arenobufagin and asarum herb. Firstly the crude drugs are shook and put into a pottery jar, and then 2,000 ml of rice wine is also put into the pottery jar; then the pottery jar is put into water and is decocted in the water; and the medicinal wine is cooled down and sealed in a container when the 2,000ml of rice wine is decocted to 1,000ml. As the analgetic medicine is prepared into the wine, the volatilization of the medicinal effect is reinforced through the rice wine. The medicinal wine which is suitable for the pain or anesthesia of local organs has a low side effect and does not impact normal biophysical activities after the sense of people returns.
ZEMBRACE SymTouch injection contains sumatriptan succinate, a selective 5-HT1B/1D receptor agonist. Sumatriptan succinate is chemically designated as 3-[2-(dimethylamino) ethyl]-N- methyl-indole-5-methanesulfonamide succinate (1:1), and it has the following structure:

The empirical formula is C14H21N3O2S•C4H6O4, representing a molecular weight of 413.5. Sumatriptan succinate is a white to off-white powder that is readily soluble in water and in saline.

ZEMBRACE SymTouch is a clear, colorless to pale yellow, sterile, nonpyrogenic solution for subcutaneous injection. Each 0.5 mL of ZEMBRACE SymTouch contains 4.2 mg of sumatriptan succinate equivalent to 3-mg of sumatriptan (base) and 4.15 mg of sodium chloride, USP in Water for Injection, USP.

The pH range of solution is approximately 4.2 to 5.3 and the osmolality of injection is approximately 291 mOsmol (275 to 315 mOsmol).
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disorder characterized by the progressive loss of motor neurons, with genetic and environmental factors contributing to its complex pathogenesis. Dysregulated immune responses and altered energetic metabolism are key features, with emerging evidence implicating the gut microbiota (GM) in disease progression. We investigated the interplay among genetic background, GM composition, metabolism, and immune response in two distinct ALS mouse models: 129Sv_G93A and C57Ola_G93A, representing rapid and slow disease progression, respectively.Using 16 S rRNA sequencing and fecal metabolite analysis, we characterized the GM composition and metabolite profiles in non-transgenic (Ntg) and SOD1G93A mutant mice of both strains. Our results revealed strain-specific differences in GM composition and functions, particularly in the abundance of taxa belonging to Erysipelotrichaceae and the levels of short and medium-chain fatty acids in fecal samples. The SOD1 mutation induces significant shifts in GM colonization in both strains, with C57Ola_G93A mice showing changes resembling those in 129 Sv mice, potentially affecting disease pathogenesis. ALS symptom progression does not significantly alter microbiota composition, suggesting stability.Additionally, we assessed systemic immunity and inflammatory responses revealing strain-specific differences in immune cell populations and cytokine levels.Our findings underscore the substantial influence of genetic background on GM composition, metabolism, and immune response in ALS mouse models. These strain-specific variations may contribute to differences in disease susceptibility and progression rates. Further elucidating the mechanisms underlying these interactions could offer novel insights into ALS pathogenesis and potential therapeutic targets.
Dry eye and persistent epithelial defects (PEDS) following LASIK and PRK are one of the most common conditions encountered by refractive surgeons and their patient's today.¹-⁴ They are associated with significant clinical morbidity in patients resulting in minor problems such as discomfort, to extreme debilitation such as visual loss. There is no accepted definition of persistent epithelial defect (PED) that includes a time period of recovery. We favor the definition given in one text "... when the epithelium fails to re-grow over a defect within the expected time course.⁵ The causes of PED are diverse, with several definite etiologies' including dry eyes, limbal stem cell deficiency, diabetes mellitus and neurotrophic problems. A variety of treatment modalities have been described for PED. The elimination of predisposing associated risk remains a key factor in the management process. Therefore, to prevent and manage this common disorder it is important to have an understanding of the pathophysiology of dry eye after LASIK and PRK. This includes and understanding of the relationship and interaction between inflammation, sensory denervation and essential fatty acid pathways. Reports of clinical efficacy of anti-inflammatory therapies for treatment of dry eye disease provide direct proof of the principle that inflammation is involved in the etiology of dry eye disease. Research has shown that the omega-3 polyunsaturated fatty acids are some of the most effective natural anti inflammatory agents available. The active ingredients in omega 3, EPA ( Eicosapentanoic acid ) which is a 20 carbon omega 3-fatty acid with 5 double-bonds , and DHA ( docosahexanoic acid )which is 22 carbon omega-3 fatty acid with 6 double bond, both found in certain fish oils enhance the conversion of COX ( cyclooxygenase) to prostaglandin E3. A natural anti inflammatory agent, prostaglandin E3 competitively inhibits the effects of the arachidonic acid conversion to prostaglandin E2, a highly inflammatory substance. Prostaglandin E3 also inhibits the synthesis of TNFα and IL-1β, both of which are inflammatory leukotrienes, also by competitive inhibition.⁶ʹ⁷ By decreasing inflammation and stimulating aqueous tear production in rabbits cAMP has been shown to stimulate aqueous tear secretion in dry eye. Furthermore, by decreasing inflammation and augmenting oil and water layers of the tear film, omega-3 supplementation with fish oil rich in EPA may improve both the lipid and aqueous component of the tear film. This may improve surgical outcomes by stabilizing the tear film, reducing epithelial defects and promoting wound healing
BACKGROUND: The transcription factor SALL4 is associated with embryonic pluripotency and has proposed as a novel immunohistochemistry (IHC) marker for diagnosing germ cell tumours. SALL4 comprises three isoforms, and SALL4-A being the full-length isoform. Studying its isoforms could revolutionize testicular cancer prognosis and subtype differentiation.
METHODS: The expression and clinical significance of isoform 'A' of SALL4 was evaluated in 124 testicular germ cell tumours (TGCTs) subtypes, adjacent 67 normal tissues and 22 benign tumours, using immunohistochemistry on tissue microarrays (TMA).
RESULTS: A statistically significant higher expression of nuclear and cytoplasmic SALL4-A was detected in TGCTs histological subtypes and benign tumours compared to the normal tissues. Seminoma and yolk sac tumours had the highest nuclear and cytoplasmic expression of SALL4-A. A significant correlation was detected between the higher nuclear expression of SALL4-A and increased pT stages (P = 0.026) in seminomas. Whereas in embryonal carcinomas, cytoplasmic expression of SALL4-A was associated with the tumour recurrence (P = 0.04) and invasion of the epididymis (P = 0.011).
CONCLUSIONS: SALL4-A isoform expression in the cytoplasm and nucleus of TGCTs may be associated with histological differentiation. In the seminoma subtype of TGCTs, higher expression of SALL4-A may be used as a predictive indicator of poorer outcomes and prognosis.
PURPOSE: To obtain an inhibitor consisting of a high protein material derived from brewers grain and capable of suppressing food allergy attributable to a food by taking the inhibitor together with the food and to obtain and drink compounded with the inhibitor. CONSTITUTION: This is food allergy inhibitor containing a high protein material derived from brewers grain whose protein content is increased, as an active component. The high protein material derived from brewers grain consists of granules separated from coats of brewers grain. The granules preferably contains protein of 40-60wt.%, preferably 45-70wt.%, lipid of 12-18wt.%, preferably 1-3wt.% as fat, fiber of 2-6wt.%, preferably 3-6wt.% and ash of 1-4wt.% in terms of dried material. Further, regarding food and drink, it is added to a basic food at the ratio of the high protein material derived from brewers grain: an allergen protein=1:2 to 1:5 (in terms of crude protein). The causaive agent of food allergy is preferably an albumen-derived protein or casein.
The incidence of adverse events during treatment with nifedipine extended-release tablets in doses up to 90 mg daily were derived from multi-center placebo-controlled clinical trials in 370 hypertensive patients. Atenolol 50 mg once daily was used concomitantly in 187 of the 370 patients on nifedipine extended-release tablets and in 64 of the 126 patients on placebo. All adverse events reported during nifedipine extended-release tablets therapy were tabulated independently of their causal relationship to medication.

The most common adverse event reported with nifedipine extended-release tablets was peripheral edema. This was dose related and the frequency was 18% on nifedipine extended-release tablets 30 mg daily, 22% on nifedipine extended-release tablets 60 mg daily and 29% on nifedipine extended-release tablets 90 mg daily versus 10% on placebo.

The following adverse events have been reported rarely in patients given nifedipine in coat core or other formulations: allergenic hepatitis, alopecia, anaphylactic reaction, anemia, arthritis with ANA (+), depression, erythromelalgia, exfoliative dermatitis, fever, gingival hyperplasia, gynecomastia, hyperglycemia, jaundice, leukopenia, mood changes, muscle cramps, nervousness, paranoid syndrome, purpura, shakiness, sleep disturbances, Stevens-Johnson syndrome, syncope, taste perversion, thrombocytopenia, toxic epidermal necrolysis, transient blindness at the peak of plasma level, tremor and urticaria.
The local exercise therapy group focused on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients trained with the support of a physiotherapist. The physiotherapist gradually increased the intensity of the exercises improving muscle endurance. The exercises were supplemented with mobilisations of the patellofemoral joint. Twice a week, patients trained at home following a prescribed exercise program writing down their work-out in an exercise journal.
PURPOSE: To cross-culturally adapt the Spinal Cord Injury Pain Instrument (SCIPI) into a simplified Chinese version (SC-SCIPI) and verify reliability and validity in screening for neuropathic pain in SCI patients.
METHODS: A preliminary validation study was conducted to screen for neuropathic pain after SCI using SCIPI. A total of 130 patients with SCI treated at Shanghai Changhai Hospital were enrolled. Results for internal consistency, reliability and construct validity were compared with those of the Douleur Neuropathique (DN4), Leeds Assessment of Neuropathic Pain Questionnaire (LANSS), Neuropathic Pain Questionnaire (NPQ), ID Pain scale and VAS pain scale.
RESULTS: The SCIPI was successfully translated into Chinese and expert consensus was reached on final adapted version of SC-SCIPI. For test-retest, SC-SCIPI total score was 2.35 ± 1.75 in first round and 2.35 ± 1.76 in second round. Cronbach α coefficient of SC-SCIPI was 0.909, indicating good internal consistency. Pearson correlation coefficient (r) showed that SC-SCIPI correlated well with LANSS, DN4, NPQ and ID pain; and correlated fairly well with VAS, indicating good construct validity.
CONCLUSION: SC-SCIPI demonstrates excellent internal consistency, reliability and good construct validity in Chinese patients with neuropathic pain, suggesting that SC-SCIPI is applicable in clinical practice to screen patients for neuropathic pain. IMPLICATION FOR REHABILITATIONThe Spinal Cord Injury pain Instrument has been cross-culturally adapted into a simplified Chinese version (SC-SCIPI).The SC-SCIPI showed excellent test-retest reliability and good construct validity.The 4-item SC-SCIPI is quite convenient to complete and it might be a useful instrument for routine application in patients with SCI for rehabilitation.
This is a prospective within-patient clinical study to assess the accuracy of ICG SLNB compared to standard dual-tracer SLNB in breast cancer patients treated with neoadjuvant chemotherapy. For SLNB, triple localization of the sentinel lymph nodes using blue dye, Tc-99m and ICG will be utilized in each patient.
Training was performed three times a week for five weeks. Each session began with a 2 minute warm up, and concluded with a 3 minute cool down. Following the warm-up, participants performed 20 minutes of arm cycling at a self-selected cadence at 45-65% of their peak power output. Total training duration was 25 mins.
Caudal anesthesia is the most common technique of epidural anesthesia in children. Caudal anesthesia is recommended for most surgical procedures of the lower part of the body, including herniorrhaphies; operations on the urinary tract, anus, and rectum; and orthopedic procedures on the pelvic girdle and lower extremities. Many anesthetic agents have been used for caudal anesthesia in pediatric patients, with lidocaine and Bupivacaine being most common. The major problems associated with this technique are the limited duration of analgesia and unwanted motor blockade.

Addition of medications that prolong analgesia after a single shot caudal block has been investigated. Several authors have mentioned a special interest in using an opioid like morphine in caudal block for postoperative analgesia. When low dose morphine is used, the side effects are lower than when higher dose of morphine are used. A larger and definitive study is needed to compare very low dose morphine via caudal administration and caudal block without Opioid with regard to duration of analgesia and frequency of side effects. We plan to conduct a chart review in our center on pediatric patients that went to urological, orthopedic, and general surgery procedures for which caudal block were given and compare the effectiveness and side effects of very low dose morphine and caudal block without Opioid.
For the first 2 cycles, RTX 375 mg/m\^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 2.4 mg/kg will be administered by IV infusion on Day 2 to Arm B participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop PD would be further treated with RTX 375 mg/m\^2 followed by pinatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. A study utilizing a radio labeled alclometasone dipropionate ointment formulation was performed to measure systemic absorption and excretion. Results indicated that approximately 3% of the steroid was absorbed during 8 hours of contact with intact skin of normal volunteers.

Studies performed with alclometasone dipropionate ointment indicate that this product is in the low to medium range of potency as compared with other topical corticosteroids.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to carbamyloxy-compounds of the formula (I):   wherein R 1  is taken among group including alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl and substituted heteroaryl; R 2  represents alkyl; R 1  and R 2  in common with nitrogen atom bound with R 2 . and SO 2 -- -group bound with R 1  can form heterocyclic or substituted heterocyclic group; R 3  represents hydrogen atom being when R 2  doesn't form heterocyclic group with R 1  then R 2  and R 3  in common with nitrogen atom bound with R 2  and carbon atom bound with R 3  can form heterocyclic or substituted heterocyclic group; R 5  represents   wherein   is taken among group including O-Z-  and O-Z-R 12  wherein R 8  and   are taken independently among group including hydrogen atom, alkyl, substituted alkyl, heterocyclic and wherein R 8  and   are combined to form heterocycle or substituted heterocycle; R 12  is taken among group including heterocycle and substituted heterocycle and Z represents C(O)-; Ar represents aryl, heteroaryl, substituted aryl or substituted heteroaryl; x is a whole number from 1 to 4; Q represents -C(X)NR 7 - wherein R 7  represents hydrogen atom; X represents oxygen atom; and to its pharmaceutically acceptable salts; to compounds of the formula IA wherein radical R 6 , representing alkoxy-group, substituted alkoxy-group, cycloalkoxy-group or NH-adamantyl are taken instead hydroxyl group by C-end. Invention relates also to two pharmaceutical compositions showing ability to block or inhibit cellular adhesion and comprising compound of the formula (I) or compound of the formula IA as an active component and to method for binding VLA-4 in biological sample and to method for treatment of inflammatory states in mammalian patient. EFFECT: valuable biological and medicinal properties of compounds. 30 cl, 3 tbl, 348 ex
FIELD: microbiology, biotechnology, pharmacy. SUBSTANCE: invention relates to manufacturing probiotic bacterial preparations and can be used in veterinary science and medicine for prophylaxis and treatment of infectious diseases in animals and humans and for correction of microbiocenosis also. For preparing probiotic bacterial preparation cellular walls of symbiotic strain of non-toxicogenic diphtheria corynebacteria, Corynebacterium diphtheriae tox- 5047 GISK named for L.A. Tarasevitch are used. Proposed probiotic is harmless, method for its preparing shows high technological features and useful for using in different medicinal formulations - capsules, powders, ointments, aerosols, drops, suppositories and so on that provides the enhanced effectiveness in prophylaxis and treatment of infectious diseases in animals and humans. EFFECT: improved preparing method, valuable properties of preparation. 4 tbl, 10 ex